iRadimed Corporation (IRMD) Director Monty K. Allen Sells 1,898 Shares
iRadimed Corporation (NASDAQ:IRMD) Director Monty K. Allen sold 1,898 shares of the company’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $13.95, for a total transaction of $26,477.10. Following the transaction, the director now owns 9,062 shares of the company’s stock, valued at approximately $126,414.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
iRadimed Corporation (IRMD) traded down $0.45 during mid-day trading on Friday, reaching $13.10. 12,083 shares of the company’s stock traded hands, compared to its average volume of 14,167. iRadimed Corporation has a fifty-two week low of $7.85 and a fifty-two week high of $15.00. The company has a market capitalization of $143.02, a price-to-earnings ratio of 104.23 and a beta of 1.61.
iRadimed (NASDAQ:IRMD) last released its quarterly earnings data on Monday, October 30th. The medical equipment provider reported $0.07 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.35. iRadimed had a net margin of 6.51% and a return on equity of 4.58%. The business had revenue of $5.69 million during the quarter, compared to analyst estimates of $5.60 million. During the same quarter last year, the business earned $0.14 earnings per share. iRadimed’s quarterly revenue was down 25.9% compared to the same quarter last year. analysts anticipate that iRadimed Corporation will post 0.05 EPS for the current fiscal year.
Hedge funds have recently added to or reduced their stakes in the business. Ameriprise Financial Inc. bought a new position in iRadimed during the second quarter valued at $2,954,000. Menta Capital LLC raised its stake in shares of iRadimed by 5.7% in the second quarter. Menta Capital LLC now owns 70,476 shares of the medical equipment provider’s stock valued at $606,000 after acquiring an additional 3,823 shares during the period. Citigroup Inc. raised its stake in shares of iRadimed by 50.8% in the second quarter. Citigroup Inc. now owns 16,082 shares of the medical equipment provider’s stock valued at $138,000 after acquiring an additional 5,418 shares during the period. Federated Investors Inc. PA raised its stake in shares of iRadimed by 7.5% in the second quarter. Federated Investors Inc. PA now owns 40,400 shares of the medical equipment provider’s stock valued at $347,000 after acquiring an additional 2,807 shares during the period. Finally, Neuberger Berman Group LLC raised its stake in shares of iRadimed by 23.3% in the second quarter. Neuberger Berman Group LLC now owns 18,500 shares of the medical equipment provider’s stock valued at $159,000 after acquiring an additional 3,500 shares during the period. Institutional investors and hedge funds own 13.83% of the company’s stock.
Several research firms have commented on IRMD. Roth Capital began coverage on shares of iRadimed in a research report on Tuesday, October 31st. They set a “buy” rating and a $16.00 price objective for the company. Credit Suisse Group began coverage on shares of iRadimed in a research report on Monday, November 27th. They set a “buy” rating and a $19.00 price objective for the company. ValuEngine upgraded shares of iRadimed from a “sell” rating to a “hold” rating in a research report on Friday, October 6th. Finally, Zacks Investment Research lowered shares of iRadimed from a “buy” rating to a “hold” rating in a research report on Monday, October 2nd. Two equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. iRadimed has an average rating of “Buy” and a consensus price target of $15.33.
TRADEMARK VIOLATION WARNING: “iRadimed Corporation (IRMD) Director Monty K. Allen Sells 1,898 Shares” was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.watchlistnews.com/iradimed-corporation-irmd-director-monty-k-allen-sells-1898-shares/1754690.html.
iRadimed Company Profile
IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.
Receive News & Ratings for iRadimed Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.